Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

March 14th 2025

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Maintenance OSE2101 Plus FOLFIRI Meets Primary OS End Point in Advanced/Metastatic PDAC

March 12th 2025

Maintenance treatment with OSE2101 plus FOLFIRI after FOLFIRINOX induction chemotherapy displayed positive topline results in advanced/metastatic PDAC.

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors

March 11th 2025

SAR444200-mediated targeting of GPC3-expressing solid tumors was safe and showed early signs of antitumor activity in a phase 1/2 study.

The OncFive: Top Oncology Articles for the Week of 3/2

March 9th 2025

Tislelizumab regimen wins approval in ESCC, perioperative durvalumab plus chemotherapy boosts EFS in gastric/GEJ cancer, and more from OncLive this week.

Perioperative Durvalumab Plus Chemo Meets EFS End Point in Resectable Gastric/GEJ Cancer

March 7th 2025

Perioperative durvalumab plus FLOT improved event-free survival in resectable gastric or gastroesophageal junction cancer.

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC

March 7th 2025

Nivolumab plus ipilimumab was approved by the European Commission for first-line, unresectable or advanced HCC.

177Lu-edotreotide Radiopharmaceutical Therapy Prolongs PFS vs Everolimus in SSTR+ GEP-NETs

March 6th 2025

Treatment with 177Lu-edotreotide significantly improved PFS and numerically increased OS vs SOC everolimus in grade 1 or 2 SSTR-positive GEP-NETs.

Data Compilation Highlights Potential of SON-1010 to Enhance Therapeutic Efficacy in Solid Tumors

March 5th 2025

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.

SWOG S1815 Shows Need for Subgroup-Specific Triplet Chemotherapy Assessment in Biliary Tract Cancer

March 5th 2025

Rachna Shroff, MD, MS, FASCO, discusses the potential role for nab-paclitaxel plus gemcitabine and cisplatin in select patients with biliary tract cancers.

Nogapendekin Alfa Inbakicept/CAR-NK Wins FDA RMAT Designation for Lymphopenia Reversal in Metastatic Pancreatic Cancer

March 5th 2025

The FDA granted RMAT designation to nogapendekin alfa inbakicept/CAR-NK for lymphopenia reversal in patients with advanced or metastatic pancreatic cancer.

Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward

March 5th 2025

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

FDA Approves First-Line Tislelizumab Plus Chemotherapy for Unresectable or Metastatic ESCC

March 4th 2025

The FDA has approved tislelizumab-jsgr plus chemotherapy for frontline use in adult patients with advanced esophageal squamous cell carcinoma and PD-L1 expression.

Dr Lee on the Rationale for Using Integrative Medicine in Patients With GI Cancers

March 4th 2025

Richard T. Lee, MD, discusses research showing the benefits of acupuncture, ginger, and ginseng for improving symptoms in patients with GI cancers.

Dr Shroff on the Addition of Nab-Paclitaxel to Gemcitabine/Cisplatin in Biliary Tract Cancer

March 3rd 2025

Rachna Shroff, MD, MS, FASCO, discusses the efficacy of nab-paclitaxel plus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancer.

T-DXd Improves OS in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma

March 3rd 2025

T-DXd improved overall survival in unresectable/metastatic HER2-positive gastric/GEJ adenocarcinoma after a trastuzumab-containing regimen.

Dr Li on the Casdozokitug/Atezolizumab/Bevacizumab in Unresectable HCC

February 28th 2025

Daneng Li, MD, discusses a trial evaluating casdozokitug plus atezolizumab and bevacizumab in unresectable, locally advanced or metastatic HCC.

Data Continue to Reshape Treatment Considerations Across Advanced GI Malignancies

February 25th 2025

Mohammed Najeeb Al Hallak, MD, MS explores treatment considerations in advanced pancreatic, colorectal, and neuroendocrine cancers.

Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

February 24th 2025

Yelena Y. Janjigian, MD, discusses 5-year follow-up findings for nivolumab plus chemotherapy vs chemotherapy alone in gastric/GEJ adenocarcinoma.

RZ-001 Earns FDA Fast Track Designation in HCC

February 21st 2025

RZ-001 has received FDA fast track designation for the treatment of patients with hepatocellular carcinoma.

Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

February 21st 2025

Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.